• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Chronic Disease

Black men less likely to receive follow-up for elevated prostate cancer marker, PSA

bys25qthea
April 7, 2013
in Chronic Disease, Oncology
Reading Time: 3 mins read
Black men less likely to receive follow-up for elevated prostate cancer marker, PSA
Share on FacebookShare on Twitter

Image: PD

1. Black men under 65 are less likely to receive recommended diagnostic follow-up testing after an elevated prostate specific antigen (PSA) result than white men of the same age. 

2. Poor diagnostic follow-up may help explain higher rates of prostate cancer mortality among black men. 

Study Rundown: This study found that black men under 65 were significantly less likely to receive appropriate follow-up testing after an elevated PSA screening test compared to white men of the same age. This is concerning because black men are at higher risk for developing prostate cancer and experience higher rates of prostate cancer mortality. These findings generate questions regarding whether racial differences in follow-up to the racial disparity in mortality due to treatment delay and whether racial differences in access to care is responsible since this racial disparity in follow-up was significant only in men >65, ineligible for Medicare.

A key limitation of this study is that the reason for lack of follow-up was not assessed, whether it was due to patient non-compliance, lack of provider recommendation, or lack of access. Without clear characterization of the barriers to follow-up, interventions cannot be developed. Moreover, PSA screening is a limited test and only represents one step of many in the diagnosis and treatment of prostate cancer. Further studies are needed to definitively link lower rates of follow-up testing to differences in mortality.

Click to read the study in Cancer 

RELATED REPORTS

bpMRI associated with higher false positive rate than PSA for prostate cancer screening

Novartis: ARV-766 is an androgen receptor degrader efficacious in treating metastatic prostate cancer

Risk of short-term prostate-specific antigen recurrence and failure in patients with prostate cancer

Click to read an accompanying editorial in Cancer 

In Depth [secondary analysis of a prospective, randomized trial]: The study used data from the screening arm of the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial to evaluate the relationship between race and diagnostic follow-up care after an elevated PSA (prostate-specific antigen) level. Men who had a PSA level >4 ng/mL at any time during the study were included and follow-up was a composite variable defined as repeat PSA, a prostate biopsy or both within 9 months. Self-identified racial group and multiple secondary variables were included in a mixed-effect multivariable model. Results were stratified by age, (<65 or >=65) to account for Medicare eligibility.

Of the 6924 eligible men with an elevated PSA, 4,413 (70%) underwent follow-up within 9 months. Black men <65 years were 45% less likely to undergo follow-up than white men of the same age (OR=0.55, 95% CI, 0.37-0.82, p=.003). There was no racial difference seen in men 65 and older. 

By Maren Shapiro and Leah Hawkins

More from this author: More U.S. women using emergency contraception pill, No cost contraception reduces unintended pregnancies, Active-Duty U.S. servicewomen have higher rates of unintended pregnancy

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: PLCOprostate specific antigenPSA
Previous Post

Group incentives promote employee weight loss

Next Post

The RE-LY trial: Dabigatran non-inferior to warfarin in preventing strokes in patients with atrial fibrillation [Classics Series]

RelatedReports

Computer-extracted MRI features help distinguish benign from malignant prostate lesions
Oncology

bpMRI associated with higher false positive rate than PSA for prostate cancer screening

June 14, 2024
Non-invasive prenatal testing linked to decreased diagnostic testing
Pharma

Novartis: ARV-766 is an androgen receptor degrader efficacious in treating metastatic prostate cancer

May 19, 2024
Testosterone replacement in male cancer survivors helps improve body composition
Chronic Disease

Risk of short-term prostate-specific antigen recurrence and failure in patients with prostate cancer

November 18, 2023
Patient Basics: Prostate-Specific Antigen Blood Test (PSA Test)
Oncology

Variation in prostate cancer screening rates associated with subsequent metastatic prostate cancer incidence

October 30, 2022
Next Post
Classics Series, Landmark Trials in Medicine

The RE-LY trial: Dabigatran non-inferior to warfarin in preventing strokes in patients with atrial fibrillation [Classics Series]

Classics Series, Landmark Trials in Medicine

The AFFIRM trial: Rate-control vs. rhythm-control in atrial fibrillation [Classics Series]

New clinical prediction model helps emergency physicians identify high-priority febrile children

New clinical prediction model helps emergency physicians identify high-priority febrile children

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

5-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • The rate of urethrocutaneous fistula following caudal and penile blocks for hypospadias repair may be similar
  • Adjuvant chemotherapy not linked to improved outcomes in localized appendiceal adenocarcinoma
  • Deep learning model improved cancer recurrence prediction for pediatric glioma using serial imaging
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

5-day free trial · cancel anytime

Start 5-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free · only $4.16/month

Start 5-day free trial

Then $49.90/year. Manage renewal in your account.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.